Cencora (COR) Reports 5.5% Revenue Growth

By Chris Stiles • Wednesday, February 04 12:04 • Permanent Link

Cencora, Inc. (NYSE: COR) has reported its fiscal 2026 first-quarter results, showcasing a 5.5% year-over-year increase in revenue to $85.9 billion. The company's GAAP diluted earnings per share (EPS) for the first quarter of fiscal 2026 stood at $2.87, a growth from $2.50 in the prior year's first quarter. Adjusted diluted EPS, a non-GAAP financial metric excluding specific items, experienced a 9.4% increase to $4.08 in the fiscal first quarter from $3.73 in the prior year's first quarter.

Cencora's adjusted operating income guidance has been raised to a growth range of 11.5% to 13.5%, up from the previous range of 8% to 10%. This adjustment primarily reflects the completion of the acquisition of OneOncology and the performance of the U.S. healthcare solutions segment. The company has also reaffirmed its adjusted diluted EPS guidance range at $17.45 to $17.75 for fiscal 2026.

The company's net income attributable to Cencora, Inc. rose to $797 million on an adjusted basis, up from $560 million on a GAAP basis. Operating income increased to $1.1 billion on an adjusted basis from $760 million on a GAAP basis.

The completion of the acquisition of OneOncology has been highlighted as a strategic move, deepening Cencora's partnership with physicians leading in cancer care. The company's president and chief executive officer, Robert P. Mauch, expressed confidence in Cencora's position to drive continued value for all stakeholders and deliver on its purpose, particularly through the execution of its pharmaceutical-centric strategy.

Following these announcements, the company's shares moved -0.14%, and are now trading at a price of $354.85. For the full picture, make sure to review Cencora's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.